10月30日 - ** Arcus Biosciences RCUS.N股价盘后下跌 5.7%，报 19.05 美元，该公司正寻求股票融资
** 专注于开发癌症、炎症和自身免疫疾病疗法的生物制药公司开始发行股票 (link)；交易规模未披露
** Leerink Partners 和高盛联合账簿管理人
** 总部位于加利福尼亚州海沃德的公司拥有约 1.08 亿股流通股，市值约 20 亿美元
** 周四股价收于 20.19 美元，下跌 0.5%，年初至今上涨约 36
** 13 位分析师中有 11 位将 RCUS 评为 "强力买入 "或 "买入"，2 位评为 "持有"；根据 LSEG 的数据，PT 中值为 29 美元，高于一个月前的 25 美元。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.